A single‐chain antibody construct with specificity of a natural IgM antibody reduces hepatic ischemia reperfusion injury in mice

Abstract

AbstractNatural immunoglobulin M (IgM) antibodies have been shown to recognize post‐ischemic neoepitopes following reperfusion of tissues and to activate complement. Specifically, IgM antibodies and complement have been shown to drive hepatic ischemia reperfusion injury (IRI). Herein, we investigate the therapeutic effect of C2 scFv (single‐chain antibody construct with specificity of a natural IgM antibody) on hepatic IRI in C57BL/6 mice. Compared with PBS‐treated mice, C2 scFv‐treated mice displayed almost no necrotic areas, significant reduction in serum ALT, AST and LDH levels, and significantly reduced in the number of TUNEL positive cells. Moreover, C2 scFv‐treated mice exhibited a notable reduction in inflammatory cells after hepatic IRI than PBS‐treated mice. The serum IL‐6, IL‐1β, TNF‐α and MPC‐1 levels were also severely suppressed by C2 scFv. Interestingly, C2 scFv reconstituted hepatic inflammation and IRI in Rag1−/− mice. We found that C2 scFv promoted hepatic cell death and increased inflammatory cytokines and infiltration of inflammatory cells after hepatic IRI in Rag1−/− mice. In addition, IgM and complement 3d (C3d) were deposited in WT mice and in Rag1−/− mice reconstituted with C2 scFv, indicating that C2 scFv can affect IgM binding and complement activation and reconstitute hepatic IRI. C3d expression was significantly lower in C57BL/6 mice treated with C2 scFv compared to PBS, indicating that excessive exogenous C2 scFv inhibited complement activation. These data suggest that C2 scFv alleviates hepatic IRI by blocking complement activation, and treatment with C2 scFv may be a promising therapy for hepatic IRI.